Phase 2 N=100 The Effect of Tranexamic Acid on Postpartum Hemorrhage During and After Cesarean Delivery
Hemorrhage
Primary: The Amount of Hemorrhage During Cesarean Delivery and Within 2 Hours Afterward — 260; 380 ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=225 GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
Carcinoma, Renal Cell
Primary: Overall Response by RECIST Criteria — 3; 75; 101; 24 participants
Phase 2 N=83 A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma
Melanoma
Primary: Overall Best Response — 10; 1; 9; 31 participants
Phase 2 N=98 Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women
Advanced Breast Cancer
Primary: Percentage of Participants With Progression Free Survival (PFS) at Week 24 — 69.4; 73.5 Percentage of participants
Phase 2 N=83 Acupressure and Relaxation for Nausea Control
Nausea
Primary: Five-day Nausea Diary — 2.0; 2.1; 2.1; 1.9 Units on scale — p=0.932
Phase 2 N=83 Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator Tiotropium
Chronic Obstructive Pulmonary Disease
Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) Following 7 Days of Treatment — 1.317; 1.333; 1.374; 1.385 Liters
Phase 2 N=281 Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Safety of Treatment With NVA237 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) — 26; 26; 24; 3 Participants
Phase 2 N=201 Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
Non-small Cell Lung Cancer
Primary: Overall Survival (OS) of Patients Receiving Pralatrexate vs. Erlotinib — 6.7; 7.0 Months Survival
Phase 2 N=151 Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement
Diabetic Macular Edema
Primary: Difference Between the Baseline Level of Visual Acuity (Letters) of the Study Eye and the Mean Visual Acuity Averaged Over All Monthly Post-baseline Assessments From…
Phase 2 N=185 Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).
Sickle Cell Disease
Primary: Number of Participants With Adverse Events After Start of ICL670 — 131; 49; 1; 2 participants
Phase 2 N=40 Long-Term Study of Nitisinone to Treat Alkaptonuria
Alkaptonuria
Primary: Change in Total ROM Worse Hip — -9.1; 1.6 degrees
Phase 2 N=22 Safety and Efficacy of Alendronate (Fosamax) in Children With Osteoporosis
Osteoporosis
Primary: Number of Participants With Improvement in Bone Mineral Density (BMD) of Spine After Therapy — 10; 9 participants
Phase 2 N=242 Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery
Bloodloss · Surgical Procedures, Operative
Primary: Cumulative Volume of Packed Red Blood Cells Transfused — 1223.2; 623.5 mL — p=0.001
Phase 2 N=31 Efficacy of ArTiMist™ in Children
Falciparum Malaria
Primary: Parasitological Success Defined as a Reduction in Parasite Count of ≥ 90% of Baseline at 24 Hours After the First Dose — 14; 10 participants — p=0.17
Phase 2 N=38 Etanercept for Treatment of Hidradenitis
Hidradenitis Suppurativa
Primary: 50% Reduction in Physician's Global Assessment Score (Percent of Participants) — 20 percentage of participants